Natera at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Natera at ASHG 2026 in Montréal: 3 presentations (2 posters, 1 platform talk).

Organization	ASHG 2026 Attendance
Natera San Carlos, California	1 Senior Vice President of Laboratory Affairs & Executive Laboratory Director · 1 Laboratory Genetic Counselor - Organ Health · 1 Senior Bioinformatics Scientist
natera.com\|LinkedIn Public company~3,000 people Natera sells cell-free DNA testing and molecular diagnostics for oncology, women’s health, organ health, and rare disease. Natera partnered with Susan G. Komen to accelerate breast cancer awareness and education, including understanding of MRD testing. › Natera partnered with Susan G. Komen to accelerate breast cancer awareness and education, including understanding of MRD testing. 2026-08 · source Natera and Angiex will use Signatera ctDNA testing to assess treatment response for Angiex's investigational antibody-drug conjugate AGX101. 2026-08 · source Natera launched a major enhancement to its Panorama NIPT test, upgrading its prenatal screening offering. 2026-08 · source Source: company newsroom Q2 2026 revenue $752.8M, up 37.7% › FY2026 revenue guidance of $2.85B-$2.91B reflects strong, accelerating growth across its testing portfolio. · 2026-08-06 “Total revenues were $752.8 million ... an increase of 37.7%; Natera anticipates 2026 total revenue of $2.85 billion to $2.91 billion.” Source: results release Currently hiring: 50 open roles › Source: careers page	Talk Thu Oct 22 8:45 am Part of Machine Learning-Driven Approaches to Variant Classification and Prioritization Evaluating performance and reproducibility of generative artificial intelligence models for autonomous variant classification Room 510/Level 5 Collaborators: UConn Health Artificial intelligenceGenetic testingLaboratory genetics and genomicsVariant interpretation Poster Fri Oct 23 2:30 pm Part of Mendelian Phenotypes Poster Friday Session Renal-predominant presentation of pathogenic PTPN11 variants delays recognition of Noonan Syndrome and leads to nephrology-based diagnosis Exhibit & Poster Hall · Board 1124F Collaborators: Alberta Children's Hospital Mendelian disorderGenotype-phenotype correlationsClinical geneticsGenetic testing Poster Fri Oct 23 2:30 pm Part of Cancer Poster Friday Session A Scalable Computational Pipeline for Opportunistic Viral Detection from Existing Whole-Exome Sequencing Tumor Data. Exhibit & Poster Hall · Board 1004F BioinformaticsCancerComputational toolsDiagnostics

Organization

ASHG 2026 Attendance

San Carlos, California

1 Senior Vice President of Laboratory Affairs & Executive Laboratory Director · 1 Laboratory Genetic Counselor - Organ Health · 1 Senior Bioinformatics Scientist

natera.com|LinkedIn

Public company~3,000 people

Natera sells cell-free DNA testing and molecular diagnostics for oncology, women’s health, organ health, and rare disease.

Natera partnered with Susan G. Komen to accelerate breast cancer awareness and education, including understanding of MRD testing.

›

Natera partnered with Susan G. Komen to accelerate breast cancer awareness and education, including understanding of MRD testing.

2026-08 · source

Natera and Angiex will use Signatera ctDNA testing to assess treatment response for Angiex's investigational antibody-drug conjugate AGX101.

2026-08 · source

Natera launched a major enhancement to its Panorama NIPT test, upgrading its prenatal screening offering.

2026-08 · source

Source: company newsroom

Q2 2026 revenue $752.8M, up 37.7%

›

FY2026 revenue guidance of $2.85B-$2.91B reflects strong, accelerating growth across its testing portfolio. · 2026-08-06

“Total revenues were $752.8 million ... an increase of 37.7%; Natera anticipates 2026 total revenue of $2.85 billion to $2.91 billion.”

Source: results release

Currently hiring: 50 open roles

›

Source: careers page

Talk

Thu Oct 22
8:45 am

Part of Machine Learning-Driven Approaches to Variant Classification and Prioritization

Evaluating performance and reproducibility of generative artificial intelligence models for autonomous variant classification

Room 510/Level 5

Collaborators: UConn Health

Artificial intelligenceGenetic testingLaboratory genetics and genomicsVariant interpretation

Poster

Fri Oct 23
2:30 pm

Part of Mendelian Phenotypes Poster Friday Session

Renal-predominant presentation of pathogenic PTPN11 variants delays recognition of Noonan Syndrome and leads to nephrology-based diagnosis

Exhibit & Poster Hall · Board 1124F

Collaborators: Alberta Children's Hospital

Mendelian disorderGenotype-phenotype correlationsClinical geneticsGenetic testing

Poster

Fri Oct 23
2:30 pm

Part of Cancer Poster Friday Session

A Scalable Computational Pipeline for Opportunistic Viral Detection from Existing Whole-Exome Sequencing Tumor Data.

Exhibit & Poster Hall · Board 1004F

BioinformaticsCancerComputational toolsDiagnostics

Instantly find 20 buyers from Natera

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction